Uncategorized
Kala Pharmaceuticals raises $11.5 million to advance ophthalmic programs
Kala Pharmaceuticals has secured $11.5 million in Series A equity financing to help move two of its ophthalmic platforms through clinical proof of concept, according to a company news release.Kala focuses on products designed to penetrate the mucosal barrier to treat a variety of diseases. This funding will help advance programs focused on topical treatment of ocular inflammation and wet age-related macular degeneration, the release said.